An Indian company, Aurobindo Pharma has been quoted as saying it is likely to buy two pharma companies worth 10 million euro each, open offices in 10 countries and establish a packaging, warehouse and manufacturing hub in Malta.

The company has just won regulatory approval to sell its cefdinir oral suspension, a generic version of Abbott Laboratories’ antibiotic Omnicef, in the US.

The US Food and Drug Administration said in its website that it has allowed Hyderabad-based Aurobindo Pharma to sell the generic drug, which is used to treat ear, sinus, throat and skin infections.

Omnicef generated $637 million in sales last year for Abbott Park, Illinois-based Abbott.

Aurobindo Pharma, which has plans to emerge as a billion dollar company by 2009-2010, is enhancing its presence in Europe by investing $100 million in phases.

Aurobindo also may make strategic investments worth $10 million in the Gulf Cooperation Council countries.

It is also setting up an active pharmaceutical ingredients manufacturing plant at Annapolis in Brazil investing around $8 million.

Aurobindo already has a manufacturing unit in New Jersey, in the US.

With over 117 filings to its credit, the company has emerged as a leader in filing drug master files for APIs in the US. The company has filed over 107 abbreviated new drug applications in the US.